Switch theme
Sign up to access all valuation multiples
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
2019
78
LTM Revenue $5.5M
LTM EBITDA n/a
$327M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Dianthus Therapeutics has a last 12-month revenue of $5.5M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Dianthus Therapeutics achieved revenue of $6.2M and an EBITDA of -$101M.
Dianthus Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Dianthus Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $2.8M | $6.2M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$47.8M | -$101M | XXX | XXX | XXX |
| EBITDA Margin | -1692% | -1627% | XXX | XXX | XXX |
| Net Profit | -$28.5M | -$43.6M | XXX | XXX | XXX |
| Net Margin | -1008% | -699% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Dianthus Therapeutics's stock price is $19.
Dianthus Therapeutics has current market cap of $601M, and EV of $327M.
See Dianthus Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $327M | $601M | XXX | XXX | XXX | XXX | $-2.80 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Dianthus Therapeutics has market cap of $601M and EV of $327M.
Dianthus Therapeutics's trades at 60.0x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Dianthus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Dianthus Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $327M | XXX | XXX | XXX |
| EV/Revenue | 52.5x | XXX | XXX | XXX |
| EV/EBITDA | -3.2x | XXX | XXX | XXX |
| P/E | -7.1x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -4.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpDianthus Therapeutics's NTM/LTM revenue growth is -35%
Dianthus Therapeutics's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $1.4M for the same period.
Over next 12 months, Dianthus Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Dianthus Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Dianthus Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 121% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -1627% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 112% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -1662% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.1M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.4M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 401% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 1333% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 1734% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Dianthus Therapeutics acquired XXX companies to date.
Last acquisition by Dianthus Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Dianthus Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Dianthus Therapeutics founded? | Dianthus Therapeutics was founded in 2019. |
| Where is Dianthus Therapeutics headquartered? | Dianthus Therapeutics is headquartered in United States of America. |
| How many employees does Dianthus Therapeutics have? | As of today, Dianthus Therapeutics has 78 employees. |
| Who is the CEO of Dianthus Therapeutics? | Dianthus Therapeutics's CEO is Mr. Marino Garcia. |
| Is Dianthus Therapeutics publicy listed? | Yes, Dianthus Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Dianthus Therapeutics? | Dianthus Therapeutics trades under DNTH ticker. |
| When did Dianthus Therapeutics go public? | Dianthus Therapeutics went public in 2023. |
| Who are competitors of Dianthus Therapeutics? | Similar companies to Dianthus Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Dianthus Therapeutics? | Dianthus Therapeutics's current market cap is $601M |
| What is the current revenue of Dianthus Therapeutics? | Dianthus Therapeutics's last 12-month revenue is $5.5M. |
| What is the current EV/Revenue multiple of Dianthus Therapeutics? | Current revenue multiple of Dianthus Therapeutics is 60.0x. |
| What is the current revenue growth of Dianthus Therapeutics? | Dianthus Therapeutics revenue growth between 2023 and 2024 was 121%. |
| Is Dianthus Therapeutics profitable? | Yes, Dianthus Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
